Daito Pharmaceutical Company Limited operates within the Medicinals and botanicals sector. In addition to historical fundamental analyses, the complete report available to purchase compares Daito Pharmaceutical Company Limited with three other companies in this sector in JAPAN : Koa Shoji Holdings Co Ltd (2020 sales of 16.03 billion Japanese Yen [US$154.57 million] of which 64% was Drug substance sales business), JCR Pharmaceuticals Co., Ltd. (24.78 billion Japanese Yen [US$238.89 million] of which 100% was Medical and Research Equipment Business), and Fuji Pharma Company Limited (33.79 billion Japanese Yen [US$325.76 million] ).

Sales Analysis. During the year ended May of 2020, sales at Daito Pharmaceutical Company Limited were ¥44.99 billion (US$433.72 million). This is an increase of 9.4% versus 2019, when the company's sales were ¥41.13 billion. This was the fifth consecutive year of sales increases at Daito Pharmaceutical Company Limited (and since 2015, sales have increased a total of 32%). Sales of Drug Substance saw an increase of 9.7% in 2020, from ¥22.08 billion to ¥24.21 billion. Not all segments of Daito Pharmaceutical Company Limited experienced an increase in sales in 2020: sales of Health Food Other fell 16.9% to ¥250.03 million. (However, this segment's sales were only a very small portion of the company's overall sales).